Germline genetics and different responses to different types of ADT

Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …

FDA approves the first 7 T MRI device for clinical use in the US

So for those currently dissatisfied with the capabilities of 1.5 T and 3 T MRI imaging technology, the US Food and Drug Administration has just approved a 7 T MRI device called a “Siemens Magnetom Terra”. … READ MORE …

Contemporary rates of overall and prostate cancer-specific mortality in Norway

A newly published study in the journal Urology (“the Gold journal”) has reported data on risk of death from prostate cancer and other causes among > 3,000 contemporary patients diagnosed with non-metastatic prostate cancer in 2004-2005. … READ MORE …

5-year data from another large series of men on active surveillance

A new article in the Scandinavian Journal of Urology has provided 5-year outcomes data from a large, prospective, single-center study of men in Denmark initially managed on active surveillance. … READ MORE …

The role of mpMRI in monitoring of men on active surveillance

At least one paper has stated that some 40 percent of men diagnosed with low-risk prostate cancer here in the US are now being initially managed on active surveillance. If active surveillance is being done properly, this is a good thing! However, … READ MORE …

Newly diagnosed? Free webinar on Wednesday, October 11

Prostate Cancer International is conducting a series of free webinars for patients and caregivers in October, November, and December.  Next Wednesday, October 11th, at 2:00 p.m. Eastern Time, Jan Manarite will lead a webinar for newly diagnosed prostate cancer patients. … READ MORE …

Patients’ understanding of the risks and benefits of first-line treatment

A newly published article in BJU International has (finally) proven something many prostate cancer educators and advocates have known for years: many patients have a very poor appreciation of the risks and benefits of their differing treatment options at the time they make decisions about first-line treatment for localized prostate cancer. … READ MORE …